Item 2.02 Results of Operations and Financial Condition

On January 28, 2021, Adamis Pharmaceuticals Corporation (the "Company") filed with the Securities and Exchange Commission ("SEC") a preliminary prospectus supplement (the "Preliminary Prospectus Supplement"), pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act") in connection with a proposed public offering of shares of its common stock, which contained information regarding the Company's preliminary estimates of its cash and cash equivalents as of December 31, 2020. The Company preliminarily estimates that its cash and cash equivalents as of December 31, 2020 was approximately $6.9 million. This preliminary estimate is not a comprehensive statement of the Company's financial results for the fiscal year ended December 31, 2020, has not been reviewed by our independent registered public accounting firm and is subject to change upon completion of our financial statement closing procedures. The Company expects to complete its audited consolidated financial statements for the year ended December 31, 2020 subsequent to the completion of the Offering. It is possible that we or our independent registered public accounting firm may identify items that require us to make adjustments to the estimate of our cash and cash equivalents balance set forth above and those changes could be material. Accordingly, undue reliance should not be placed on this preliminary estimate.

The information provided in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or Sections 11 and 12(a)(2) of the Securities Act, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.




Item 8.01 Other Events

The Preliminary Prospectus Supplement contained an updated summary description of certain aspects of the Company's business. Accordingly, the Company is filing this information with this Current Report on Form 8-K for the purpose of supplementing and updating disclosures contained in the Company's prior filings with the SEC, including those discussed in the Company's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by the Company's subsequent filings with the SEC. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits.



Exhibit No.      Exhibit Description

  99.1           Updated Summary Business Information
104              Cover page interactive data file (embedded within the Inline XBRL
                 document).

© Edgar Online, source Glimpses